Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases
25 oct. 2018 07h30 HE
|
Spark Therapeutics, Inc.
The Eye Want 2 Know digital resource helps patients and their families in the U.S. living with an inherited retinal disease (IRD) learn about genetic testing and includes a “Find A Provider” tool to...
Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate
08 oct. 2018 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
Spark Therapeutics Annuncia il Parere positivo del CHMP per la Terapia Genica una tantum LUXTURNA® (voretigene neparvovec) nell’Unione europea
25 sept. 2018 12h49 HE
|
Spark Therapeutics, Inc.
LUXTURNA diventerebbe la prima terapia genica per una malattia genetica approvata sia negli USA sia nella UE LUXTURNA sarebbe la prima e unica terapia genica approvata nell’UE per il trattamento di...
Spark Therapeutics gibt zustimmende Bewertung des Ausschusses für Humanarzneimittel für die einmalig verabreichte Gentherapie LUXTURNA® (Voretigen Neparvovec) in der Europäischen Union bekannt
25 sept. 2018 12h49 HE
|
Spark Therapeutics, Inc.
LUXTURNA wäre die erste Gentherapie für eine genetische Erkrankung, die sowohl in den USA als auch in der EU zugelassen ist LUXTURNA wäre die erste und einzige...
Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union
21 sept. 2018 07h17 HE
|
Spark Therapeutics, Inc.
LUXTURNA would be first gene therapy for a genetic disease approved in both U.S. and EU LUXTURNA would be first and only gene therapy approved in EU to treat patients with vision loss due to...
Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress
07 août 2018 07h30 HE
|
Spark Therapeutics, Inc.
As of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show: A 97-percent reduction in annualized bleeding rate (ABR) and 97-percent reduction in annualized...
Spark Therapeutics wurde vom Philadelphia Business Journal zum zweiten Mal in Folge als einer von Philadelphias „besten Arbeitgeber“ ausgezeichnet
03 août 2018 15h23 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar sind,...
Spark Therapeutics Recognized for Second-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
03 août 2018 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics veranstaltet am Dienstag, 7. August, um 8.30 Uhr ET (Ostküstenzeit) eine Telefonkonferenz, um über die Unternehmens- und Finanzergebnisse des zweiten Quartals und die neuesten Geschäftserfolge zu sprechen
31 juil. 2018 14h16 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, July 31, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar sind,...
Spark Therapeutics to Host Conference Call on Tuesday, Aug. 7 at 8:30 a.m. ET to Discuss Second Quarter Results and Recent Business Highlights
31 juil. 2018 07h30 HE
|
Spark Therapeutics, Inc.
PHILADELPHIA, July 31, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...